ADC Therapeutics SA
No enriched coverage for $ADCT in the last 7 days.
No SEC Form 4 filings for $ADCT in the last 30 days.
See all $ADCT insider activity →ADC Therapeutics (ADCT) reported Q2 earnings with steady ZYNLONTA revenue at $18.6M and reduced net loss to $16.6M. The FDA raised safety concerns about a combination trial, creating regulatory uncertainty. The company cut operating expenses by 29% and has cash to last into 2028. Short interest is at 5.70% of the float.
ADC Therapeutics (ADCT) reported Q2 2026 net product revenue of $18.6M, up from $18.1M YoY. Net loss narrowed to $16.6M ($0.11 per share) from $56.6M YoY. Cash reserves totaled $219.1M, expected to last into 2028. The company reduced operating expenses by 22% YoY and cut 17% of its workforce. FDA raised concerns about the LOTIS-5 trial, prompting ADCT to assess regulatory paths for ZYNLONTA. Management plans to seek breakthrough designation for ZYNLONTA plus glofitamab combination therapy.
ADC Therapeutics SA (ADCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026 LOTIS-7, LOTIS-5 and MZL IIT data submitted for p
Recent ADCT coverage spans market movers, earnings and corporate actions.
Short-term pressure from FDA concerns may weigh on price, but improved cash position and reduced loss provide upside potential.
Improved financial metrics and cost reductions may support short-term price stability, but ongoing regulatory concerns add downside risk.
Near-term trading focus is the FDA feedback on LOTIS-5 and the company’s next regulatory steps, alongside ongoing LOTIS-7 and ASH data timelines.
Near-term trading focus is regulatory clarity for ZYNLONTA combinations after the FDA pre-sBLA feedback, alongside ongoing commercialization and cost actions.
This reads as a sentiment and optionality trade (oversold bounce plus M&A chatter) rather than a new clinical or regulatory datapoint.
AlphAI scores every news story that mentions ADCT with an AI model for sentiment and relevance, and aggregates insider trades from ADC Therapeutics SA's SEC EDGAR Form 4 filings. Figures refresh continuously.
ADC Therapeutics (ADCT) reported Q2 earnings with steady ZYNLONTA revenue at $18.6M and reduced net loss to $16.6M. The FDA raised safety concerns about a combination trial, creating regulatory uncertainty. The company cut operating expenses by 29% and has cash to last into 2028. Short interest is at 5.70% of the float.
3 min readADC Therapeutics (ADCT) reported Q2 2026 net product revenue of $18.6M, up from $18.1M YoY. Net loss narrowed to $16.6M ($0.11 per share) from $56.6M YoY. Cash reserves totaled $219.1M, expected to last into 2028. The company reduced operating expenses by 22% YoY and cut 17% of its workforce. FDA raised concerns about the LOTIS-5 trial, prompting ADCT to assess regulatory paths for ZYNLONTA. Management plans to seek breakthrough designation for ZYNLONTA plus glofitamab combination therapy.
3 min readADC Therapeutics SA (ADCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026 LOTIS-7, LOTIS-5 and MZL IIT data submitted for p
6 min readADC Therapeutics (NYSE: ADCT) reported Q2 2026 net product revenue of $18.6M (vs. $18.1M in Q2 2025) and cash and cash equivalents of $219.1M as of June 30, 2026. The FDA held a pre-sBLA meeting on LOTIS-5; the company is assessing the regulatory path. LOTIS-7 enrollment is complete and data were submitted to ASH.
6 min readThe Russell 2000 stayed near 3,000 with little movement, while seven small-cap stocks gained at least 28% in four sessions. The article cites July surges for Orthofix (OFIX) on CMS reimbursement reversal, REGENXBIO (RGNX) on FDA resubmission alignment and AbbVie milestone, Verastem (VSTM) on short-squeeze setup, ADC Therapeutics (ADCT) rebound, Sable Offshore (SOC) refinancing, Rapid7 (RPD) takeover speculation, and Crinetics (CRNX) surge toward an offer price.
7 min readADC Therapeutics SA (ADCT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001771910 0001771910 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readADC Therapeutics (NYSE: ADCT) said enrollment is complete in its LOTIS-7 Phase 1b trial of ZYNLONTA (loncastuximab tesirine-lpyl) plus glofitamab (COLUMVI) for relapsed/refractory DLBCL. 100 patients were dosed at 150 µg/kg; full data are expected in Q4 2026. Prior reported ORR was 89.8% with 77.6% CR.
3 min readADC Therapeutics (NYSE: ADCT) announced a strategic reorganization, planning to cut its global workforce by about 17% to generate annualized estimated savings of roughly $10M. The company said it is preparing for regulatory and clinical milestones, including an FDA pre-sBLA meeting in August 2026 and an sBLA submission in Q4 2026, plus full LOTIS-7 data by end-2026.
3 min readADC Therapeutics reported topline Phase 3 LOTIS-5 results for ZYNLONTA plus rituximab in relapsed/refractory DLBCL. The combo met the primary endpoint for progression-free survival (6.1 vs 4.7 months vs R-GemOx) and showed no detrimental overall survival impact, with higher response rates (58.1% vs 45.2%) and longer complete responses. Safety differed, with more serious events and Grade 5 events in the ZYNLONTA arm. Shares fell 49.68% to $1.55 premarket.
4 min readADC Therapeutics SA (NYSE:ADCT) shares rose 0.4% to $3.4450 on Thursday after trading between $3.46 and $3.43. Volume was about 454,455 shares, down 60% vs. average. Analysts: HC Wainwright reiterated Buy with an $8 target; RBC reiterated Outperform with $6; Weiss reiterated Sell. In May 4 earnings, the company reported EPS of -$0.21 vs -$0.19 expected and revenue of $20.85M vs $19.99M.
4 min read
